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BREAST IMPLANTS: CHOICES WOMEN
THOUGHT THEY MADE
Nearly two million women- received breast implants between
1962 and 1991: eighty percent for cosmetic purposes, and twenty
percent for reconstructive surgery following mastectomies. 1 From
their inauspicious beginnings as a tool for Japanese prostitutes during
World War II to enlarge their breasts for American servicemen,2
implants have now been deemed crucial to post-mastectomy
recipients3 and other women seeking self-improvement." Implants are
© Copyright 1993 by the New York Law School Journal of Human Rights.
'John R. Easter ct al., Medical "State of the Art"for the Breast Implant Litigation,
in BREAST IMPLANT Lrrio. 1, 12 (Law Journal Seminars-Press 1992). This Note will
focus primarily on silicone-filled implants. Food and Drug Administration ("FDA")
estimates released in 1988 indicate that only 15% of implant surgeries were for
reconstructive purposes, while 85% were for cosmetic purposes. Teich v. FDA, 751 F.
Supp. 243, 245-46 (D.D.C. 1990). Mastectomies involve "excision or amputation of the
breast." WEBSTER'S NEw COLLEGIATE DICTIONARY 701 (8th ed. 1981).
2 Primetime Live: Inflammatory Reaction (ABC television broadcast, Feb. 13, 1992)
available in LEXIS, News Library, ABCNEW File [hereinafter Primetime]. Women
have actually sought, "for many complex reasons," to enhance their breast size since
1916. Stephen Lichtenstein, A Discussion of the Silicone Gel-Filled Breast Implant
Controversy, 12 REv. LITIG. 205, 206-07 (1992). The FDA banned direct injection of
silicone into women's breasts in 1965. 93 Plaintiffs in Implant Case Against All
Manufacturers, MED.-LEGAL ASPECTS OF BREAST IMPLANTS, Feb. 1993, at 3.
1 Healthweek. Living in the 90's (CNN television broadcast, Nov. 16, 1991)
available in LEXIS, News Library, CNN File. In a chilling twist of fate, some women
with a genetic predisposition to breast cancer removed their breasts as a preventative
measure and inserted implants thereafter. Sally Jessy Raphall, "I'm So Scared of
Cancer, I Had My Healthy Breast Removed" (Multimedia Entertainment television
broadcast, Dec. 17, 1992) (transcript on file with the New York Law School Journal of
Human Rights).
" Nurse and mother Karen Bulleya said upon receiving the implants that she was
"really pleased with the surgery." Bulleya continued: "I think I even wrote the surgeon
a letter telling him, you know, how much that it did for my self-esteem." Face to Face
with Connie Chung: Breast Implants: Risky Business (CBS television broadcast, Nov. 8,
1991) (transcript on file with the New York Law School Journal of Human Rights)
[hereinafter Chung]. Another woman said she needed her implants "to feel fabulous."
Donahue: Move Body Fat From Your Buttocks to Your Breasts (Multimedia
Entertainment television broadcast, Dec. 1, 1992) (transcript on file with the New York
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thus both a "device" and a "cosmetic" product,' but most importantly,
they have contributed to the psychological, physiological, and even
economic6 well being of millions'of women. Imagine, nonetheless,
the misfortune of at least one reconstructive surgery patient who had
to lament the dread of losing both breasts not just once, but twice.7
Since over half of the women who received implants did so
merely for cosmetic purposes,' they may seem to be a potentially less
sympathetic group. The unacceptable fact remains that almost all of
the women who received implants did so without being fully informed
of the risks involved.' Aside from a desire to bolster their own self-
image,1" and their ability to attract men," women for the last thirty
Law School Journal of Human Rights) [hereinafter Donahue]. Body image is "the
driving force" for most women. CNN Special-A New Look at Breast Implants (CNN
television broadcast, Dec. 31, 1992) available in LEXIS, News Library, CNN File. Dr.
Joan Read, a psychologist, says that virtually all of the women she has worked with
chose to have breast implants "because they felt like their body was not what they
wanted it to look like." Id. Consider also that the common philosophy in the 1950s was
"'What God has forgotten, replace with cotton."' In the 1970s and 1980s, this mantra
became "'What God has foregone, replace with silicon.'" Aaron M. Levine,
Introduction to LITIGATING BREAST IMPLANT CASES 9, 11 (1992).
S 21 U.S.C. § 321(h) (1992) provides in pertinent part: "the term 'device"' means
an "implant .. .which is ... intended to affect the structure or any function of the
body of man or other animals, and which does not achieve any of its primary intended
purposes through chemical action within or on the body of man or other animals and
which is not dependent upon being metabolized for the achievement of any of its primary
intended purposes." § 321(i) provides in pertinent part: the term "'cosmetic' [means]
... articles intended to be ... introduced" into the "human body or any part thereof"
for "beautifying, promoting attractiveness, or altering the appearance." 21 U.S.C. §
321(i) (1992). Prior to the 1976 Medical Device Amendments, silicone implants were
classified as drugs for purposes of FDA regulation. Teich v. FDA, 751 F. Supp. 243,
246 n.2 (D.D.C. 1990).
6 Aside from Japanese prostitutes, consider entertainers and actresses who receive
implants to boost their earnings.
7 Chung, supra note 4, at 4.
8 See supra note 1 and accompanying text.
' See Marilyn Quayle Following Hearings On Breast Implants, UPI, Feb. 20, 1992,
available in LEXIS, News Library, UPI File ("[R]ight now no one in the general public
has enough facts to make an intelligent decision.").
'0 See supra note 4 and accompanying text.
n See sources cited supra notes 2, 4. Aaron M. Levine states matter-of-factly:
"Since Venus de Milo, women's bustlines have been idolized." Levine supra note 4, at
11. Arthur Caplan, director of the University of Minnesota Center for Biomedical
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years have been the subjects of a clinical trial, 2 unprotected by the
agency that is supposed to stand between the manufacturer and the
consumer-the Food and Drug Administration ("FDA"). 3 This Note
will address how the judiciary and breast implant victims are bringing
to light the realities of a controversy that strikes at the core of
women's health issues and corporate ethics.14 The FDA's role and
its laxity with respect to breast implant devices will also be
addressed, as will what the consumer may expect in the future from
this government agency.
This Note will first focus on breast implant victims and what
is known about their plight. Next, the judiciary's role, starting with
the action of the Judicial Panel on Multidistrict Litigation
("J.P.M.L.") will be examined. 5 Thereafter, the Note will discuss
the effect of the statute of limitations on breast implant litigation, and
the roles of doctors and manufacturers. The third section discusses
the FDA's role, addressing the agency's failure to test health care
Ethics, said "I think having large breasts is an attempt to please males. It's a cultural
fetish." Judy Foreman, Implants: Is Uninformed Consent a Woman's Right?, BOSTON
GLOBE, Jan. 13, 1992, at 25.
12 See Chung, supra note 4, at 3. See also Leslie Berkman, 0. C. Whistle Blower
Says Women with Implants Are "Guinea Pigs', L.A. TIMEs, Feb. 22, 1992, at A2. One
former engineer for Dow Coming said he "hopes women will be given information to
truly convince them that they are human guinea pigs if the [silicone gel] devices are
allowed back on the market." Id. One physician testifying on behalf of the defendants
commented that the implants had "a tendency to rupture after a number of years, a fact
which he said he learned from experience, not from the manufacturer's warning." Toole
v. McClintock, 778 F. Supp. 1543, 1547 (M.D. Ala. 1991), vacated, 999 F.2d 143
(1lth Cir. 1993). Doctors at the Dow Coming Center to Aid Medical Research injected
humans with silicone without telling them they were part of an experiment or why
treatment was abruptly stopped after the first injections. Judy Foreman, Women and
Silicone: A History of Risk, BOSTON GLOBE, Jan. 19, 1992, at 1. The Center was set
up in the early 1960's to explore medical uses of silicone. Id.
13 Newsmaker Sunday: Has the Public Lost Confidence in the FDA? (CNN television
broadcast, May 19, 1991) available in LEXIS, News Library, CNN File.
14 Primetime, supra note 2, at 9.
IS Congress created the J.P.M.L. in 1968 to facilitate the litigation of civil actions
involving one or more common questions of fact, pending in different districts. 28
U.S.C.S. § 1407(a) (1988). The J.P.M.L. may transfer such cases to any district for
coordinated or consolidated pre-trial proceedings; such transfers "shall be made upon
[the J.P.M.L.'s] determination that transfers for such proceedings will be for the
convenience of parties and witnesses and will promote the just and efficient conduct of
such actions." Id.
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products adequately before approving them for general use, and the
public's loss of confidence in the agency.
Finally, the Note will look ahead by examining what the
future holds for breast implant victims. What was the medical
knowledge at the time of implantation? Doctors should have
considered that breasts are not merely ornamental appendages but are
part of women's sexual reproductive makeup. The discriminatory
ramification therein, however, is the assumption that all women seek
to bear children. The author predicts this and other questions that
will surface in litigation in the years ahead will be: was it the
doctor's duty to warn their patients that they did not know what effect
breast implants would have not only on the women themselves but on
their children as they became nursing mothers?
The cases in the coming years will also beg the issue of how
much risk we, as members of society, are willing to undertake. Must
we decide this issue to avoid joining the ranks of those who counter,
when something goes wrong, that it is someone else's fault? How
much has the manufacturing process changed over the years such that
the problems have surfaced only recently? In aiming for a reasoned
resolution to the tragedy at hand, these questions should be kept in
mind when considering the choices women-and all of the players in
the chain of creating, regulating and inserting the devices-made.
L The Victims
A. Ill Effects Known and Unknown
The risks associated with breast implants, known by the FDA
in April 1991,6 included: fibrous capsular contracture,' silicone gel
leakage and migration, infection, and early tumor detection
difficulties. 8 Additional dangers known at that time include:
15 Easter et al., supra note 1, at 14.
7 Id. Fibrous capsular contracture forms a constricting fibrous layer around the
implant, potentially producing "excessive breast firmness, discomfort, pain,
disfigurement, displacement of the implant and psychological trauma." Id.
" Id. at 15. "Even under the best of circumstances, silicone gel-filled prostheses are
likely to limit the effectiveness of the examination for breast cancer detection." Id.
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degradation of polyurethane foam-covered breast prostheses, cancer,
birth defects in association with "prolonged gel migration,"
autoimmune disease, and calcification.19
In plain but not all-inclusive terms, women report flu-like
symptoms, to wit: swollen glands, fevers, chills, sweats, sore throats,
joint pain, fatigue,2" hair loss, rheumatoid arthritis and lupus.21 Since
the FDA's moratorium on silicone implants on January 6, 1992,
thousands of women have sued their doctors and implant
manufacturers for injuries as varied as cancer, ruptured implants, and
immune system disorders.22 Children of women with the implants
also appear to be emerging as victims.23 While commenting
skeptically on the link between these illnesses and breast implants,
however, Dr. Jack Fisher points out that "[o]ver time, patients with
insulin-dependent diabetes and those who depend on dialysis
accumulate substantial bodily exposure to silicone[,] yet no systemic
illness attributable to silicone has been reported in [such patients]. ,24
19 Easter et al., supra note 1, at 14-16.
2 Chung, supra note 4, at 3.
21 Larry King Live: Are Breast Implants Safe? (CNN television broadcast, Apr. 19,
1991) available in LEXIS, News Library, CNN File [hereinafter King].
22Tamar Lewin, As Silicone issue Grows, Women Take Agony and Anger to Court,
N.Y. TIMES, Jan. 19, 1992, at Li. A growing number of medical researchers are now
linking silicone implants to immune diseases previously unknown to the medical
community. Thomas M. Burton, Research Links Silicone Version to New Diseases,
WALL ST. J., Feb. 4, 1993, at B1. Patients sampled "tested positive for antinuclear
antibodies, entities that attack the body's own tissue." Id.
' Children Injured.: 2d Generation of Implant Cases in the Making, MED.-LEOAL
ASPECTS OF BREAST IMPLANTS, Dec. 1992, at 1, 1. See Sandra G. Boodman, Breast
Implants and Birth Defects, WASH. POST, June 23, 1992, at Z14. Although there is no
scientific proof to demonstrate birth defect links, a Toronto doctor has found that among
1,000 implant patients studied, children born after their mothers received implants
experience more health problems than babies born before the implant surgery. Problems
include joint pain, digestive disorders and swollen lymph nodes; one woman who has had
an implant since she was 14 (after a tumor was removed) said that her breast-fed son's
symptoms are "a lot like mine." Id. See also Burton, supra note 22, at BI (quoting a
doctor who stated that silicone may cross into breast milk and not turn up for several
years; examinations have revealed a number of children whose diseases are thought to
be related to nursing with silicone implants).
Jack C. Fisher, M.D., Sounding Board.: The Silicone Controversy-When Will
Science Prevail?, 326 NEw ENO. J. MED. 1696, 1703 (1992).
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Lastly, while arguments with respect to causation of cancer
and implants exist for both sides' counsel, Livshits v. Natural Y
Surgical Specialties, Inc. 25 demonstrates the fragility of courtroom
attempts at linking polyurethane foam-covered implants with the
disease. Considered at one time to be the first successful "cause and
effect" linkage,26 the Livshits court award was substantially modified
on the disqualification of the plaintiff's expert on the question of what
was the actual cause of any acceleration of cancer that occurred in the
plaintiff's breast.27 A study published by The New England Journal
of Medicine in June 1992 found (to the likely disappointment of the
plaintiffs bar) that the only cancers ever credibly linked to silicone
were connective-tissue sarcomas that appeared in rodent species
susceptible to cancer.28 TDA,2 9 a known carcinogen in animals, is
now known, however (to the likely satisfaction of the plaintiff's bar)
to be released from the polyurethane foam covering of at least one
particular line of breast implants.3 0
B. Ramtfications of the Tenuous Disease Causality Link
Although scientists are unable to establish a direct causal link
between autoimmune disease31 and breast implant defects, "the
number of [such] cases reported weaken[s] the case for chance
2 No. 87 Civ. 2403 (WK), 1991 WL 261770 (S.D.N.Y. Nov. 27, 1991).
' J. Douglas Peters & Margaret M. Aulino, Breast Implants: Science and Litigation,
in BREAST IMPLANT LITIo. 67, 70 (Law Journals Seminars-Press 1992).
'7 1991 WL 261770, at *7, *8-'11.
1 See Fisher, supra note 24, at 1704.
29 TDA is the abbreviation for the chemical 2,4 Toluene Diamine. Denise M.
Dunleavy, TDA in Breast Implants: Wat Lawyers Should Know, MED.-LEGAL
AsPECTS OF BREAST IMPLANTS, Dec. 1992, at 6, 6.
3 Id.
31 See infra note 36. In November 1992, researchers at the Scripps Research
Institute strengthened the link between silicone implants and autoimmune disorders.
Thomas M. Burton, Breast Implants Raise More Safety Issues, WALL ST. J., Feb. 4,
1993, at Bl. Evidence revealed that women whose implants leaked experienced
autoimmune symptoms sooner than those whose implants remained intact. Id.
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association. 32  Because of the lack of conclusive evidence,"
however, "lawyers will be able to find suitable quotations from the
medical literature whether they are representing the plaintiff or the
defendant."34  Until researchers are able to provide a definitive
answer to the causation question, the issue will continue to be
plaintiffs' greatest obstacle in suits against breast implant
manufacturers.
32 Easter et al., supra note 1, at 22. Patients who suffered memory and sensory loss
experienced recoveries within days of having their silicone implants removed. Burton,
supra note 22, at Bl, B4. A pharmacologist similarly stated that "it's difficult to explain
that [recovery] away." Id. Breast implant expert Pierre Blais states that "if you look
at [a breast implant], which is leaking like a sieve, and you look at this person and if
she's got an unusual disease, you'd better have a very good argument to say that this
didn't do it." Primetime Live: Desperate for Help (ABC television broadcast, June 3,
1993) available in LEXIS, News Library, ABCNEW File [hereinafter Desperate for
Help]. Recent studies have shown that some women with silicone breast implants may
develop "atypical immunologic reactions." Study Finds Implants May Cause 'Atypical'
Immune Reactions, MEALEY'S LITIO. REP., June 30, 1993, at 15. Some conclude "that
silicone breast implants may cause abnormalities of certain cells and an increased
autoimmunity." Houston Doctor Finds Immune Response, MEALEY'S LMo. REP., June
30, 1993, at 16; see Robert Steinbrook, Link Between Implants, Immune Disease Seen,
L.A. TIMES, Jan. 20, 1992, at Al (quoting Dr. Steven R. Weiss: "Out of 500 patients
with both silicone gel breast implants and possible rheumatic ailments, 125 had problems
clearly related to their implants. Of the women whose implants were removed, one-half
to two-thirds have significantly improved."). The FDA is now requiring breast implant
manufacturers to update their informed consent documents (for those women receiving
implants through goverment-approved clinical programs) based on information from
recent studies which show a possible link between silicone gel-filled implants and
autoimmune disorders. Philip J. Hilts, Two Studies Yield New Data on Breast Implants,
FDA CONSuMER, June 2, 1993, at 3.
' An FDA Advisory Panel was unable to find a causal link between cancer and
implants. See Easter et al., supra note 1, at 37-38.
Id. at 31-32, 43.
31 Lichtenstein, supra note 2, at 218. A Dow spokesperson commenting on a recent
defense victory, Turner v. Dow Coming Corp., No. 92 Civ. 150 (D. Colo. 1992), stated
that both Dow and plaintiffs studies presented at trial detailed Dow's strong scientific
story and help set precedent. Dow Corning Wins Jury Verdict in Colorado Trial,
MEALEY'S Lrrio. REP., June 30, 1993, at 8, 11. Turner sued Dow and her plastic
surgeon based on strict liability and negligence claims. id. at 8. According to her
lawyer, Ms. Turner, a former topless dancer who had aborted one child and given up
another for adoption at birth, was tried on "character assassination, not facts." Colorado
Jury Decides For Dow in Breast Implant Case, LIABILrrY WK., June 14, 1993; Michelle
Weldon, Scare Tactics Win in Breast Implant Case, PLAIN DEALER, Aug. 3, 1993, at
4C. In Mohney v. Baxter Healthcare Corp., No. 86-CV-3325 (Colo. Dist. Ct., El Paso
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In many instances, the statute of limitations may present yet
another obstacle since symptoms associated with autoimmune diseases
are slow to develop, progressive, and incurable.36 For example,
researchers have reported only four cases of systemic sclerosis37
developed by women within six to fifteen years after breast
augmentation, and point out that the number of cases "might be
affected by under-recognition of the problem or by the long latency
[period] between implantation and disease manifestation."38 This is
the reason many people are prompted to compare today's breast
implant litigation with the highly publicized Dalkon Shield or DES-
type litigation of the 1980s."9 Moreover, as in Dalkon Shield or DES
County June 25, 1993), the jury found the defendant's product did not cause the
wheelchair-bound implant recipient's neurological and autoimmune problems. Second
Colorado Jury Returns Defense Verdict, MEALEY'S LrIIo. REP., June 30, 1993, at 11.
See generally Helen E. Zukin, In Implant Cases, Attorneys Have Hurdles to Overcome,
MED.-LEGAL ASPECTS OF BREAST IMPLANTS, Feb. 1993, at 7 (discussing the issue of
causation in implant litigation).
3 See Lewin, supra note 22. The immune system usually distinguishes between
substances naturally found in the body and foreign agents, and produces antibodies to
attack only the latter category. In cases of autoimmune disease, however, the immune
system causes injury to tissue by its production of antibodies which react with normal
parts of the body. The principle autoimmune diseases possibly associated with silicone
are scleroderma, rheumatoid arthritis, and lupus. Autoimmune symptoms are referred
to as "human adjuvant disease" or "connective tissue diseases" because they effect
various connective tissues that support other internal body structures. Easter et al.,
supra note 1, at 18-19.
11 Systemic sclerosis is also known as scleroderma. STEADMAN'S MED. DICTIONARY
1263 (24th ed. 1982). Scleroderma is a potentially lethal immune-system illness
characterized by leathery hardening of the skin. Burton, supra note 22. Scleroderma can
also attack internal organs. Id.
" Easter et al., supra note 1, at 29. One case of progressive systemic sclerosis
occurred in a woman who had received silicone injections in her breasts 18 years before
the onset of symptoms. Id. at 24.
" Peters & Aulino, supra note 26, at 70; Tracey Schroth, Breast Implants: Latest
Toxic Tort, N.J. L.J., Apr. 13, 1992, at 1 (calling silicon breast implants the "litigation
nightmare" of the 1990s, replacing the Dalkon Shield of the 1970s, and DES of the
1980s); Stuart A. Schlesinger, Breast Implants and the Law, N.Y. L.J., Jan. 30, 1992,
at 3 (classifying breast implants with intrauterine devices ("IUD") and DES products by
pointing out the lag time between governmental agencies' and plaintiff attorneys'
recognition of the dangers of these products). The Dalkon Shield was a particular type
of IUD manufactured by A.H. Robins which spawned thousands of bodily injury and
wrongful death claims. Georgene M. Vairo, The Dalkon Shield Claimants Trust:
Paradigm Lost (Or Found)?, 61 FORDHAM L. REV. 617, 624-25 (1992). DES refers to
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litigation, the victims in breast implant litigation will be America's
women40 and children.4"
I. The Judiciary
Breast implant plaintiffs have faced what may be described as
"a pattern of judicial indifference and occasional hostility. "42 Indeed,
shared expert sentiment is that the need to eliminate "frivolous"
lawsuits and cut down the cost of litigation is the driving force behind
the consolidation of breast implant-type lawsuits.43 Symptomatic of
the elusiveness of which approach to take, however, is the U.S.
Senate's recent rejection of a bill which would have made it harder
for consumers to sue companies over defective products." The main
a group of estrogens prescribed to pregnant women from the late 1940s until 1971 to
prevent, inter alia, miscarriages. Myra P. Mulcahy, Proving Causation in Toxic Torts
Litigation, 11 HOFSTRA L. REv. 1299, 1315 (1983). In 1971, the FDA said DES was
ineffective and dangerous for pregnant women because studies revealed a link between
DES consumption during pregnancy and the potential development of cervical and
vaginal cancer in so-called DES daughters. Id.
4 Peters & Aulino, supra note 26, at 70; Helen E. Zukin, Breast Implant Makers
Fail to Learn Lesson of the Past, MED.-LEOAL AsPECTs OF BREAST IMPLANTs, Dec.
1992, at 3 (stating that "[als with the Dalkon Shield ... a product has been introduced
into the human body without any reliable testing to determine its safety.").
41 See supra note 23 and accompanying text. Illinois children have brought claims
against the manufacturers and component part suppliers of silicone implants alleging
damages resulting from adverse reactions at the time of their conception and/or from
being breast-fed by women with breast implants. Women, Spouses, Children File Suit in
Illinois, MEALEY'S LiTIG. REP., Feb. 22, 1993, at 24 (citing Arbus v. Aesthetech Corp.,
No. 936-930 (Cir. Ct., Cook County Jan. 25, 1993)). Aaron Levine, who
unsuccessfully litigated four second-generation DES cases, does not have much hope for
second-generation implant cases because of the evidentiary problems inherent in such
suits. Andrew Blum, Breast Implants Hurt Children?; Second-Generation Cases, NAT'L
L.J., Feb. 15, 1993, at 3. The FDA is currently working with Children Afflicted by
Toxic Substances, a private New York-based organization, to study mothers with silicone
implants in order to determine whether and how implants are affecting their children.
FDA Begins Study of Children of Women With Breast Implants, CHI. TRIB., May 7,
1993, at 7.
42 Lichenstein, supra note 2, at 211.
4 Barry Meier, Bill to Curb Consumer Lawsuits Falls Short, N.Y. TIMES, Sept. 13,
1992, at E3.
41d.
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problems cited are the percentage of damage awards that go to
lawyers and the court time consumed by lingering lawsuits. Of equal
concern, however, is how to effect change without compromising the
rights of those injured.45 One judge appeared to skate questionably
close to compromising injured parties' rights by offering one veteran
implant attorney a lead counsel role in exchange for not opposing a
class certification supported by the judge."
A. The Winners and Losers of Class Certification
Prior to the transfer of all federal claims to the Northern
District of Alabama,47 Judge Rubin (involved in an Ohio class
certification)" stated that the court had heard assertions both that
upwards of five million women may have breast implants and that
only a "minute portion of those individuals have a compensable
claim."49  The goal of certification is to ensure that all potential
plaintiffs have an opportunity to be heard, and to protect all potential
defendants from discovery harassment that would unduly interfere
with normal business operations.5 0  The Alabama Multidistrict
Litigation"1 is a result of successful efforts by both plaintiffs and
defendants who opposed conducting the breast implant cases as a
class action.5 2
45 Id.
' See Thomas M. Burton, Breast-Implant Judge's Phone Call Sparks Controversy,
WALL ST. J., Apr. 2, 1992, at B8. Judge Rubin of Ohio was trying to convince New
York Attorney Denise Dunleavy to join him in support of class certification. Id.
Plaintiffs moved prior to trial to have their actions certified as a class action pursuant to
Federal Rules of Civil Procedure 23. See Dante v. Dow Coming Corp., 143 F.R.D.
136 (S.D. Ohio 1992).
47 In re Silicone Breast Implants Products Liability Litigation, No. CV 92-P-10000-S
(N.D. Ala. June 26, 1992).
4 In re Breast Implant Litigation, No. C-1-92-057, 1992 U.S. Dist. LEXIS 10081
(S.D. Ohio Mar. 26, 1992).
491 Id. at *1.
0 Id.
s' The Alabama Multidiscrit Litigation was created by the JPML.
52 Susan C. Zuckerman, State Breast Implant Cases Aided by MDL Legwork,
MED.-LEOAL ASPECTs OF BREAST IMPLANTS, Dec. 1992, at 1.
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Whether mass tort suits such as the breast implant cases are
tried as a class or individually has a great impact on many parties,
not the least of whom are the plaintiffs.53 If the cases are tried
together, every implant recipient would probably get a small
settlement-nothing close to the multimillion dollar suits already
received by a few women.' Those who receive part of a class action
settlement may only be compensated for a fraction of their medical
costs in extreme cases.55 If the cases are tried separately, however,
11 See Judy Foreman, Lawyers Fight Over Limits of Implant Trials, BOSTON GLOBE,
May 15, 1992, at 1. Arguments against trying mass tort cases together (excepting single
mass disasters) involve issues particular to individual plaintiffs, such as timing and
manner of exposure, medical histories and alternate causes, which may predominate and
overwhelm any issues the plaintiffs happen to share in common. Sheila L. Birnbaum &
Gary E. Crawford, Consolidated Cases Raise Fairness Issues, NAT'L L. J., July 12,
1993, at 18. See Kenneth Jost, Wrestling With Mass Torts, THE RECORDER, May 18,
1993, at 1 (discussing the topic of consolidating mass tort cases in greater detail).
I Foreman, supra note 53. New York attorney Robert Gordon pointed to the
defective Bjork-Shiley heart valves as an example of plaintiffs receiving "much less than
any of them would have received by taking their cases individually to court." The
settlement reached in that class action awarded $2,500-$4,000 per plaintiff. Id. Large
verdicts in breast implant cases thus far include a $7.3 million verdict in December
1991, awarded by a jury in the United States District Court in California, Tracey
Schroth, Breast Implants: Latest Toxic Tort, N.J. L.J., Apr. 13, 1992, at 1, and $4.45
million and $5.4 million awards in 1991 in New York and Alabama cases respectively.
Mark Cusri, Betting on Silicone Gone Bad, THE RECORDER, Oct. 9, 1991, at 1. A
Texas plaintiff received a $25 million award. Johnson v. Medical Engineering Corp. et
al., No. 91-21770 (D.Ct. Tex., Dec. 23, 1992); Gary Taylor, Breast Implant Suits
Pouring In, NAT'L L.J., Jan. 18, 1993, at 3. A "take-nothing" final judgment was
entered in the Johnson case on June 28, 1993. Take Nothing Judgment Entered in
Johnson, MEALEY'S LrTIG. REP., June 30, 1993, at 11. Although the attorneys involved
declined to comment, such a judgment generally means that the case has been settled.
Id. At least one multimillion-dollar judgment has been vacated. An appellate court has
ordered a new trial in Brenda Toole's case, nullifying her $2.275 million judgement.
See Toole v. McClintock, 999 F.2d 1430 (1 lth Cir. 1993); Bill Rankin, Judge Overturns
Breast Implant Verdict-Multimillion-dollar Award Is Nullified, ATLANTA J. & CONST.,
Sept. 3, 1993, at Al.
I Robert Sullivan, editor of BREAST IMPLANT LrIGATION REPORTER, worries that
class certification may lead to the generic treatment of implant plaintiffs, irrespective of
the relative damages actually incurred by each class member, creating a situation in
which many women will receive only "a fraction of what they deserve." Schroth, supra
note 54. Commenting on the Agent Orange cases, one law school professor noted that
a class of Vietnam War veterans won $180 million which came to only a few thousand
dollars per individual plaintiff, "even for those hardest hit by medical problems."
Foreman, supra note 53.
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some plaintiffs could collect more money, but those who sue later
may get less.6 Individual claimants, and some lawyers, think there
are simply too many injuries, claims and manufacturers to make for
a good class action case, although a class action seeking medical
monitoring for women without severe injuries may be the best way
to handle those claims.57 Class certification also puts lawyers in two
camps: those who try a class action could earn millions, leaving
hundreds of other lawyers out of the loop, while an attorney litigating
a non-class action suit could produce contingency fees-approximately
one-third of any settlement reached by the parties-for all of the
individual attorneys involved. 58
Lawyers who oppose class certification fear that it would only
lead to attorney abuse of plaintiffs who have already suffered at the
hands of their doctors and the manufacturers. 59 They fear their
clients will be treated as numbers, not individuals.' Karen Koskoff,
co-chair of the breast implant litigation group at the Association of
Trial Lawyers of America, said class action suits are convenient for
greedy lawyers and defendants because the fees are shared among a
few lawyers who do little work.6' Koskoff said "everybody knows"
the class parties will settle, "forcing plaintiffs to fight over a
prearranged pot of money."62 In the case of a mandatory class,
56 Foreman, supra note 53.
£' Saundra Torry, The Race to Represent Breast Implant Victims, WASH. POST, Mar.
9, 1992, at F5.
'Id.
Foreman, supra note 53. One woman, agonizing over the type of implant to get
after her reconstructive surgery, stated that her plastic surgeon was "actually antagonistic
to [her] . . . because [she] even questioned the idea of silicone implants." Joan E.
Rigdon, Saline Implants Appear to Carry Hazards as Well, WALL ST. J., Feb. 4, 1993,
at B1.
0 Foreman, supra note 53. Martha Wivell, who heads the National Silicone Implant
Litigation Coordinating Committee, asks: "If you believed your life was drastically
affected [by an implant], would you want your case. . . lumped together with every
other person who some lawyer decides is just like you?" Id.; see Torry, supra note 57,
at F5.
61 Foreman, supra note 53.
' Id. (quoting Koskoft). An Alabama district court granted preliminary approval
to a $24 million settlement offer by Mentor Corporation, the first settlement reached
between an implant manufacturer and a plaintiffs committee. Judge Approved Settlement
on Mentor Breast Implants, LIABILITY WK., July 12, 1993. In another suit, Mentor
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which the judge chosen by the Judicial Panel on Multidistrict
Litigation may order, every implant recipient in the country,
regardless of whether a suit is filed, would have to become part of
the class in order to sue a manufacturer.63 Notwithstanding Dow
Corning's riches," other defendants may well benefit from a
mandatory class formation which is based on a finding that there is
indeed a limited pool of funds among the manufacturers.65
Corp. settled its implant claims for $25.8 million. Joanne Wojick, Implant Makers Near
a Deal,- $4.75 Billion Settlement Would Fund Claims, Bus. INS., Feb 21, 1994, at 1.
Dow Coming Corporation has proposed a $4.75 billion settlement fund to compensate
women with Dow implants. Gina Kolata, Fund Proposed for Settling Suits Over Breast
Implants, N.Y. TIMES, Sept. 10, 1993, at A16. The proposal provides awards of
$200,000 to $2 million for women who acquired one of eight diseases (scleroderma,
lupus, mixed connective tissue disease, inter alia); other women could seek lesser
amounts for removal and medical care. Id. The settlement fund would be drawn from
manufacturers, raw material providers, insurance companies, doctors, and other health
care providers. Id. The heralded "landmark" settlement will extend for 30 years, and
has been compared to the $2.4 billion Dalkon Shield settlement which was established
in 1989 after 10 years of litigation. Karen Zagor, Dow Corning Plans Implant
Fund-Proposal To Create a Landmark, FIN. TIMES, Sept. 10, 1993, at 28. The
settlement, if accepted, purportedly represents the largest payout for medical claims
ever. David R. Olmos, Dow Proposes $4.75 Billion to Settle Breast Implani Suits, L.A.
TIMES, Sept. 10, 1993, at Dl. The proposal must be approved by Judge Sam Pointer
of the District Court in Alabama, who is overseeing the class action litigation. The
settlement purportedly does not require women to take independent medical exams; their
doctor's diagnoses will suffice. Bill Rankin, Silicone Breast Implant Case Pending
Litigation, ATLANTA J. & CONST., Sept. 10, 1993, at D6.
Foreman, supra note 53.
Dow Coming's 1992 sales totaled $1.956 billion, generating profits totaling
$111.8 million, excluding the impact of special charges and accounting provisions. Dow
Corning Announces 1992 Financial Results, PR NEWSWIRE, Jan. 27, 1993, available in
LEXIS, News Library, PRNEWS File. Dow also recorded $69 million in pre-tax
revenues in 1992 to cover expenses related to the breast implant controversy. Id.
Shares of Coming Inc. stock rose $1.65 on news of the proposed $4.75 billion settlement
fund for breast implant claims. Bamaby J. Feder, Wall Street Welcomes Settlement Plan
on Breast Implants, N.Y. TIMES, Sept. 10, 1993, at D4. Dow is jointly owned by Dow
Chemical Co. and Coming Inc. Dow Corning to Turn Over Documents to FDA,
REUTERS Bus. REP., Nov. 2, 1992, available in LEXIS, News Library, REUBUS File.
Dow enjoyed the largest share, 25 %, of the silicone breast implant market based on sale
figures for the period ending in January 1992. Carol Gentry, Lifesavers Casualty of
Silicone Debate, ST. PETERSBURG TIMES, Jan. 31, 1993, at 1A.
' Foreman, supra note 53, at 4 (discussing the decline in revenues for the smaller
manufactures of breast implants). See Therese Poletti, Smaller Firms Hit Hardest by
Halt in Breast Implants, REUTER Bus. REP., Jan. 8, 1992, available in LEXIS, News
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To date, two major class actions have been certified, one in
Ohio and one in California respectively," but their certification "may
be conditional, and may be altered or amended before the decision on
the merits."67 The advantage of a class action for the judiciary is
reducing the burden on the state and federal courts of all of the
potential litigants that exist.68 Class actions and the issues therein
could potentially be taken care of in a relatively short time span, as
opposed to stretching on for decades.69 In many cases, these
advantages do not outweigh the individual litigant's interest.7 °
B. Judicial Panel on Mulidistrict Litigation
Multidistrict litigation is used for the sake of efficiency where
common questions of fact exist in suits pending before more than one
federal court or judicial district.71 Presently, approximately 3,500
federal breast implant cases have been transferred to the United States
District Court, Northern District of Alabama for coordinated and/or
consolidated pre-trial proceedings. 72 By such action, the judiciary has
recognized, as pointed out above, that the breast implant cases give
Library, REUBUS File.
" See In re Silicone Gel Breast Implants Products Liability Litigation, 793 F. Supp.
1098 (N.D.Cal. 1992); In re Breast Implant Litigation 143 Fed. R. Ser. 3d 1149 (S.D.
Ohio, Feb 14, 1990). See also Amanda Husted & Mike King, Lawsuit Awareness,
ATLANTA J. & CONST., May 20, 1992, at F3 (discussing the requirement for legal teams
heading class action suits to notify silicone implant recipients of lawsuits against
companies).
67 FED. R. Civ. P. 23(c)(1) (1990).
' See Philip J. Hilts, Decision Time Near for Implant Suits, N.Y. TIMES, Sept. 2,
1992, at C12.
6Id.
7 id.
71 See supra note 15 and accompanying text.
72 In re Silicone Gel Breast Implants Products Liability Litigation, No. CV 92-P-
10000-S (N.D. Ala. June 26, 1992) (initial case management order); MDL Panel Orders
433 Cases Transferred, MEALEY'S Lmo. REP., June 30, 1993, at 8. State courts across
the country have also consolidated their breast implant cases for pre-trial proceedings.
See, e.g., Pennsylvania Panel Adopts First-Stage Discovery Rules, Mealey's Litig. Rep.,
June 30, 1993 at 13; New Jersey Court Issues First Case Management Order, MEALEY'S
LrTIO. REP., June 30, 1993, at 14.
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"every indication of surviving many years."73 Centralization of the
class actions is necessary in order to avoid the duplication of
discovery, to ensure consistent pretrial rulings, and to conserve the
resources of the parties, their counsel and the judiciary.74
The J.P.M.L.'s forum choice engendered the kind of
acrimonious debate that supports the fears of some breast implant
lawyers who worried that their clients would suffer abuse at the hands
of class action lawyers. 75  The Panel was "troubled . . by the
volume and tone of the negative arguments with which opposing
counsel... sought to denigrate each other's forum choices, litigation
strategies and underlying motives," and reported that:
1) [P]arties in the Ohio forum have engendered a
flurry of pretrial activity in an effort to dictate our
decision on selection of the transferee court; 2) the
class in the Southern District of Ohio was certified in
a precipitous fashion, without according adequate
notice or opportunity to be heard to interested parties
nationwide; 3) defendants oppose the California forum
only because the two trials there resulted in
substantial verdicts against one of them; and 4) the
plaintiffs who favor the California forum are forum
shopping for a judge who has tried a breast implant
action in which plaintiffs prevailed.76
73 Easter et al., supra note 1, at 54.
' In re Silicone Gel Breast Implants Products Liability Litigation, 793 F. Supp.
1098, 1100 (N.D. Cal. 1992). New York attorneys on both sides have sought pretrial
consolidation of their breast implant cases in hopes of replicating the multi-district
litigation procedure that is provided for by the J.P.M.L. See Daniel Wise, Joinder of
Breast Implant Suits Seen, N.Y. L.J., Mar. 15, 1993, at 1.
75 See Foreman, supra note 53.
76 Implants Products Litigation, 793 F. Supp. at 1100.
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C. Statute of Limitations
None of the judicial orchestrations will matter to those
plaintiffs who fall outside of the statute of limitations. 77 Nationwide
trends indicate that state legislatures have sought to control the scope
of discovery in medical malpractice actions by imposing one to six
year statutes of limitation.78 In Louisiana, for instance, a medical
malpractice action may be brought either one year after the alleged
malpractice, or one year after discovery of the alleged malpractice,
but never more than three years after the alleged malpractice. 79 The
trend in breast implant cases is that the statute starts to run only when
damage to or from the implant occurs.8" The problem is that the
plaintiff may not be aware of the damage when it begins to occur and
therefore may not get the use of the full statute of limitations-be it
one, three or seven years.
The state has broad discretion to legislate statutes of
limitations which are arbitrary, and do not need to discriminate
between just and unjust claims or avoidable and unavoidable claims.8"
In barring the claim of a toxic tort victim in Schwartz v. Heyden
Newport Chem. Corp. ,82 the New York Court of Appeals found that
77 Statutes of limitations prescribe time limits on the right to bring certain causes of
action or criminal prosecutions. BLACK'S LAW DICTIONARY 835 (5th ed. 1979).
' Marc S. Firestone, Note, Prescription-What You Don't Know Can Hurt You-
Louisiana Adheres to a Three Year Limit on the Discovery Rule, 58 TUL. L. REV. 1547,
1552 (1984). Other states' prescriptive periods run as follows: California has a three
year maximum; Florida has a four year maximum; Kentucky has a four year maximum;
Nebraska has a 10 year limit; North Dakota has a six year limit; Vermont has a seven
year limit; Washington has an eight year limit. Id. at 1553 n.37.
79 Id. at 1553.
0 Lichtenstein, supra note 2, at 224 (citing Klein v. Dow Coming Corp., 661 F.2d
998, 998-99 (2d Cir. 1981) (suit initiated 14 years after implantation but one year after
rupture not time-barred), Sutlive v. Hackney, 297 S.E.2d 515, 516-18 (Ga. Ct. App.
1982) (seven years post-implant not time-barred). But compare Levenson v. Souser, 557
A.2d 1081, 1083-84 (Pa. Super. Ct. 1989) (suit initiated 25 months after cause of action
accrued time-barred under battery statute).
81 Chase Sec. Corp. v. Donaldson, 325 U.S. 304, 314 (1944) (holding that
Minnesota statute lifting statute of limitations' bar in a pending suit does not violate due
process).
s2 188 N.E.2d 142 (N.Y.) modified, 190 N.E.2d 253 (N.Y.), and cert. denied, 374
U.S. 808 (1963).
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notwithstanding the arbitrariness to "a plaintiff who could not know
he was being destroyed from within,"83 it had "no facilities to inquire
into the incidence of hardship cases under the statute, nor the
peculiarly legislative prerogative to balance the result of such an
inquiry against the countervailing considerations" " that justify statutes
of limitation. Other courts, by contrast, refuse a mechanical
application of such statutes when it would lead to a result that "no
legislator, living or dead, would ever have intended.""5 Such courts
likely agree with the New Hampshire court which emphasized that the
"'repose' of the manufacturer must give way to the welfare of the
consuming public, and that if this meant liability in perpetuity, so be
it. 86
s Id. at 145.
Id. New York Governor Mario Cuomo recently signed into law a bill that
provides women who claim they have been injured by faulty silicone implants with a
one-year time period to file suit. Update, N.Y. L.J., July 28, 1993, at 1. The law gives
claimants the benefit of the date-of-discovery rule, see infra note 90, and allows for the
revival of claims against manufacturers that may have expired more than 10 years ago.
Gary Spencer, Revival Statute Passed For Silicone Implants, N.Y. L.J., June 30, 1993,
at 1.
85 E. Scott Hackenberg, Comment, Puttering About in a Small Land: Louisiana
Revised Statutes 9:5628 and Judicial Responses to the Plight of the Medical Malpractice
Victim, 50 LA. L. REV. 815, 816 (1990) (quoting Tate, The 'New' Judicial Solution:
Occasions For and Limits to Judicial Creativity, 54 TUL. L. REV. 877, 913 (1980)). See
Billiot v. American Hosp. Supply Corp., 721 F.2d 512, 513 (5th Cir. 1983) (impleading
surgeon as a defendant more than three years after his allegedly negligent breast implant
operation found answerable in solido with manufacturer sued within a year of the first
manifestation of the damages).
" Jane M. Draper, Annotation, Statute of Limitaions: Running of Statute of
Limitations on Products Liability Claim Against Manufacturer as Affected by Plaintiff's
Lack of Knowledge of Defect Allegedly Causing Personal Injury or Disease, 91 A.L.R.3d
991, 994 (1992) (citing Nelson v. Volkswagen of America Inc., 315 F. Supp. 1120,
1122 (D.N.H. 1970)). Courts generally agree that when personal injury is suffered by
"silent and insidious impregnation as a consequence of the act or omission of another
who knows, or is charged with the responsibility of knowing, that such act or omission
may result in personal injury, and the injured person is unaware of the cause of his
injury ...no action for a tort resulting from such cause begins to accrue until the
injured person knows, or by the exercise of reasonable diligence should have discovered,
the cause of such injury" since a reasonably prudent and intelligent person could not,
without specialized knowledge, have been made aware of such cause. Id. at 994-95.
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Allen v. United States87 stated that aside from traditional
statute of limitation policy reasons,88 three elements implicit in the
statute must be examined with care: the specific information said to
be known or which should be known by each plaintiff, the time of
such knowledge, and whether the amount of information possessed in
fact by the plaintiff at the time she is charged with such knowledge
is sufficient to establish injury.89 In applying the date of discovery
rule, as opposed to the date of injury rule," courts have generally
held that an injury dates from the time the prosthesis ruptured as
opposed to the time it is implanted. 9 Illustrating the grey area in the
spectrum between an actual ruptured implant diagnosis and a
claimant's less certain notice of injury, the court in Vest v. Bossarda2
held that "a finding of reasonable suspicion on the part of the plaintiff
was insufficient to initiate the running of the statutory period. "93
Given the plethora of breast implant victims whose autoimmune
' 588 F. Supp. 247 (D. Utah 1984), rev'd on other grounds, 816 F.2d 1417 (10th
Cir. 1987), and cert. denied, 484 U.S. 1004 (1988) (federal tort action for damages
resulting from atomic testing).
' The principle consideration underlying the statutes is fairness to the defendant.
Goodman v. Mead Johnson & Co., 388 F. Supp. 1070, 1073 (D.N.J. 1974), rev'd on
other grounds, 534 F.2d 566 (3d Cir. 1976), and cert. denied, 429 U.S. 1038 (1977).
Statutes of limitations are "designed to promote justice by preventing surprises through
the revival of claims that have been allowed to slumber until evidence has been lost,
memories have faded, and witnesses have disappeared." Order of R.R. Telegraphers v.
Railway Express Agency, Inc., 321 U.S. 342, 348-49 (1944).
9 Allen, 588 F. Supp. at 346.
0 Under the discovery rule, a medical malpractice cause of action "will be held not
to accrue until the patient knows, or, in the exercise of reasonable diligence should have
known, of the alleged malpractice." Owens v. White, 380 F.2d 310, 313 (9th Cir.
1967). In contrast, the date of injury rule proclaims that the "claim accrues at the time
of discernible injury, usually the same time as the causative act." Brazzell v. United
States, 788 F.2d 1352, 1356 (8th Cir. 1986).
9' See, e.g., Klein v. Dow Coming Corp., 661 F.2d 998 (2d Cir. 1981).
92 700 F.2d 600 (10th Cir. 1983).
" Allen, 588 F. Supp. at 345.
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diseases go misdiagnosed or undiagnosed,' the Allen court's
explanation of knowledge of injury is particularly pertinent:
[It just seems to make common sense that the
running of the statute of limitations begins when
knowledge of injury and reasonable knowledge of its
cause are attained. Suspicion will not suffice, no
matter how well-founded early suspicions may appear
in retrospect. A plaintiff with the requisite quantum
of knowledge (or reason to have such knowledge) has
received-seized, grasped, understood-facts. 95
Further, the court stated, statutes of limitations "are not intended to
stimulate the filing of actions arising from injuries or causes that have
not been rationally identified. "'
Despite the inability of experts to scientifically identify
problems related with implants97 (and on top of the FDA's late
action),9' plaintiffs in some cases are barred from litigating their
claims by virtue of statutes of limitation." Such plaintiffs may only
" Typical stories include the victim who explained that for almost five years doctors
insisted she had a virus, until finally one physician told her that her system was being
poisoned by a human adjuvant disease (another name for autoimmune disease). Chung,
supra note 4, at 3. See supra note 36 and accompanying text. Another woman, Debbie
Craft, explains that doctors gave "different diagnoses for different things and never once
came out and stated: 'This is all related to your breast implants."' King, supra note 21.
" Allen, 588 F. Supp. at 345 (emphasis added).
9 Id.
' See supra part I.B.
9 The FDA restricted silicone-filled implants in April 1992, 30 years after their
introduction to consumers. See infra note 149 and accompanying text.
9 See Lewin, supra note 22, at 1. Sybil Goldrich is appealing the dismissal of her
case which she filed in 1986, less than a year after discovering her implant had ruptured.
The trial court concluded that Ms. Goldrich should have known earlier that the implant
was the root of her medical problems; she got implants in 1983 after a double
mastectomy and went through four sets of implants, repeated infections and hardening
before finding out that one of her implants had ruptured and that silicone had migrated
to her ovaries, uterus, and liver. Answering the charge that she should have known
earlier that her implants were the cause of her problems, Goldrich stated: "That's a little
strange, given that the FDA doesn't seem to have been able to establish the problems
very quickly." Id. See also Gnazzo v. Searle, 973 F.2d 136 (2d Cir. 1992) (affirming
a dismissal of a late IUD suit based on the plaintiff's suspicion nine years earlier that the
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use the equitable estoppel doctrine, provided they can show that the
defendant concealed material facts."o In medical malpractice actions,
equitable estoppel may apply if there is a "great disparity in
knowledge between the providers and the recipients of health care"
i.e. specialized knowledge of cause and effect "beyond the untutored
understanding of the average layman. "'01
D. Secrecy Rulings' °
Providing knowledge to the consuming public is often
hindered by secrecy rulings. 03 Courts may seal pre-trial and trial
information in a purported effort to avoid lengthy and costly
proceedings, and to encourage the settlement of disputes."° The
danger in this practice lies in the courts' potential to compromise on
matters which venture beyond their procedural prerogative to public
policy issues-the release of information regarding product
safety-which are more appropriately within the legislator's
purview.'15 Consumers are also left in the position of caveat
device was the source of her problem). In dissent, Justice Sweet stated that the plaintiff
did not discover her actionable harm until 1989 when doctors actually diagnosed her
ailment. Id. at 139 (Sweet, J., dissenting).
" See Olson v. A.H. Robins Co., 696 P.2d 1294, 1299 (Wyo. 1985) ("Where the
defendant has superior knowledge of the facts necessary to make out a cause of action
and fraudulently conceals those facts or misrepresents them to the detriment of the
plaintiff, equitable estoppel applies to prevent the statute of limitations from being a
defense.").
'0' Allen, 588 F. Supp. at 345, (quoting Vest v. Bossard, 700 F.2d 600, 609 n.3).
10 Three main types of court secrecy exist: 1) protective orders (designed to prohibit
parties from distributing information received during discovery to the public); 2)
confidentiality agreements (for information not already covered by a protective order,
for example, the cause of injury, the claimed product defect, or a settlement amount);
and 3) sealed court files (preventing public access). Robert L. Habush, Public
Knowledge of Private Disputes: Do Protective Orders Unduly Compromise the Public's
Right to Know?, THE BRIEF, Winter 1993, at 13, 14.
"0 See Rep. Larry Smith (D-Fla.), No More Court Secrecy on Dangerous Products,
Hous. CHRON., Mar. 13, 1992, at B15 (op-ed page essay).
IN Id.
105 Id.
1993] BREAST IMPLANTS 183
emptor.106 Several state legislatures have enacted laws prohibiting
sealed records in public hazard cases.10 7 The California legislature
has, for example, tried to prohibit "settle and seal" deals that enable
manufacturers to "sweep their misdeeds under the carpet" in product
liability cases.1"8 The bill cites the silicone breast implants
controversy as an illustration of judicial and government failure to
alert consumers to potentially defective products.'0 9 Opponents to
publication of the sealed information believe such exposure would
divulge trade secrets and worsen the recession.1 But where the
public's health and safety are at issue, the greatest danger of the
secrecy orders emerges-lawyers getting information to regulatory
agencies which the agencies should already have.1 ' Trial lawyers
106 Id.
0 The Public's Right to Know-Ending Secret Settlements to Protect Public Safety,
SEATTLE TIMEs, Feb. 5, 1992, at A6.
L- See S. 711, 1991-92 Regular Sess., 1991 California available in LEXIS, Legis
Library, STTEXT File; Carl Ingram, Bill Would Crack Secrecy in Suits on Product
Liability, L.A. TIMEs, Jan 28, 1992, at 3. The bill was not signed into law in either
1991 or 1992. Carl Ingram, Wilson Vetoes Bill to Lift Secrecy on Liability Lawsuits,
L.A. TIMES, Sept. 1992, at Al.
109 See sources cited supra note 108. Proponents of the 1992 bill include, inter alia,
the California Trial Lawyers Association, the Sierra Club, the Consumers Union, the
Center for Public Interest Law, and the American Association of Retired Persons. Id.
The Washington State Legislature has proposed a similar bill which prohibits sealing
court documents containing information about public health hazards such as breast
implants. Wash. Bill Would Bar Sealing of Records, MED-LEGAL ASPECTS OF BREAST
IMPLANTS, June 1993, at 2.
"0 Ingram, supra note 108. Opponents include the California Chamber of
Commerce, the California Manufacturers Association, and the Association for California
Tort Reform which represents insurance companies and other financial institutions,
doctors, hospitals and pharmaceutical companies. Id. Opponents argue that irrelevant
details such as employees' salaries and private medical information would be revealed
under the proposed laws. Vanessa Ho, Nader Backs Bill to Curb Secrecy in Safety
Lawsuits, SEATTLE TIMES, Feb. 14, 1992, at F4; Frank J. Dailey, Public Knowledge of
Private Disputes: Do Protective Orders Unduly Compromise the Public's Right to
Know?, THE BRIEF, Winter 1993, 13, 13 (arguing that the discretion traditionally
exercised by courts on privacy issues safeguards the rights of private parties, which in
turn encourages the free exchange of ideas vital to product improvement).
... Habush states there are innumerable examples of secret settlements with plaintiffs
(or their estates) who have been injured or killed by dangerously defective products
which have neither been recalled nor identified openly as a threat to public health.
Habush, supra note 102, at 41. FDA Commissioner David A. Kessler appears to be in
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saw documents that cast doubt on the implants' safety approximately
eight years before the FDA did."' It was only following the Hopkins
case,' when a reporter copied the trial blowups of damaging Dow
corporate memos," 4 that the FDA finally requested a moratorium on
accord. David A. Kessler, M.D., Special Report: The Basis of the FDA 's Decision on
Breast Implants, 326 NEw ENO. J. MED. 1713, 1713 (1992). Kessler suggests that
government should intervene to provide product information. Id. Proponents of secrecy
orders even argue that government agencies should have the exclusive right to force
disclosure of information about dangerous products. Habush, supra note 102, at 41.
One commentator noted that in these days of lawyer-bashing, plaintiffs' attorneys are the
forerunners in questioning the safety of implants: "The FDA and the news media are
literally a decade or more behind the trial lawyers who, in the course of representing
plaintiffs, have warned of the dangers of these silicone gel breast implants in the context
of previous actions brought for users of these products." Stuart A. Schlesinger, Breast
Implants and the Law, N.Y. L.J., Jan. 30, 1992, at 3. Consumers are said to have "the
much maligned tort system to thank for opening the [FDA] agency's eyes to the health
hazards of these [breast implant] devices and to the fact that the manufacturers were
withholding information on the dangers of silicone from consumers and from the FDA."
Sybil N. Goldrich & Kathleen W. Anneken, R.N., Product Liability Act Defeated,
COMMAND TRUST NETwORK NEWSL., Fall 1992, at 1.
11 Gina Kolata, Secrecy Orders in Lawsuits Prompt States' Efforts to Restrict Their
Use, N.Y. TIMES, Feb. 18, 1992, at D10. See Stern v. Dow Corning, No. C-83-2348-
MHP (N.D. Cal.), appeals dismissed, Nos. 85-2345, 85-2346, 1987 U.S. App. LEXIS
6517 (9th Cir. May 17, 1987). See generally Gayle L. Troutwine, Breast Implants:
Beauty Fraud, TRIAL, Aug. 1993, at 48, 49 (chronicling the extent of Dow's knowledge
of dangers posed by its products).
Hopkins v. Dow Coming, No. C88-4703 TEH, 1991 WL 328043 (N.D. Cal. Jan.
9, 1991). The case is presently on appeal in the Ninth Circuit (Case No. 92-16132).
Hufstedler and Tribe in 9th Circuit Appeal, MED.-LEOAL ASPECTS OF BREAST
IMPLANTS, July 1993, at 6.
14 John H. Kennedy, Secrecy Orders Put New Burdens on Legal System, BOsTON
GLOBE, Feb. 5, 1992, at 53. Several internal Dow documents disclosed the company's
knowledge that at least some gel implants were leaking silicone. Schroth, supra note 54.
Memos suggested salespeople change demonstration models often and clean them to get
rid of any outside oils. Id. Hopkins' lawyers obtained internal Dow memos which
revealed causal connections between implant ruptures and autoimmune system disorders.
Stephen Lichtenstein, A Discussion of the Silicone Gel-Filled Breast Implant Controversy,
12 REV. Lrrio. 205, 206-07 (1992). For a partial list of memos to and from Dow
scientists which demonstrate knowledge of problems, see Foreman, supra note 53. The
fact that Dow possessed internal documents suggesting the dangers of its product makes
this case similar to A.H. Robins' Dalkon Shield cases. Moneyline: Breast Implant
Dilemma Leads to Lawsuits (CNN television broadcast, Apr. 13, 1992) available in
LEXIS, News Library, CNN File); see Vairo, supra note 39, at 624-25 (documenting
the physical and legal consequences resulting from defects in the Dalkon Shield).
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the use of the implants. 1 5  Dan Bolton, plaintiffs attorney in
Hopkins, testified before an FDA panel in 1988, but was unable,
ironically, to provide details about the silicone implants due to
secrecy orders and agreements.11 6 Another lawyer referred to the
secrecy orders as a "systematic cover up. . . Even though nobody
would say they are doing this to hurt the public, that's the effect."" 7
In the end, injured and cash-strapped plaintiffs often have no
choice but to accept the settlements defendants dangle in front of
them in exchange for secrecy orders. 8 In a strongly worded
statement on the isue of secrecy orders, Judge Sarokin of the Federal
District Court for New Jersey opined:
In light of the current controversy surrounding breast
implants, one wonders when all industries will
recognize their obligation to voluntarily disclose risks
from the use of their products. All too often in the
choice between the physical health of consumers and
the financial well-being of business, concealment is
chosen over disclosure, sales over safety, and money
over morality. Who are these persons who knowingly
and secretly decide to put the buying public at risk
solely for the purpose of making profits and who
believe that illness and death of consumers is an
appropriate cost of their own prosperity!" 9
1s Kennedy, supra note 114, at 53.
116 Id.
"' Kolata, supra note 112, at DlO (quoting George Annas, Esq., Director of the
Program on Law, Medicine and Ethics at Boston University).
I's Id.
"19 Haines v. Liggett Group, 140 F.R.D. 681, 683 (D.N.J. 1992). Judge Sarokin
was subsequently removed from the case for the appearanceof partiality. Charles Strum,
Major Lawsuit on Smoking Dropped, N.Y. TIMEs, Nov. 6, 1992, at B1. Sarokin's harsh
words seem necessary, however. The decision whether to disclose documents under seal
truly poses a difficult challenge. Wayne L. Pines, Handling ExternalAudiences: A Guide
for the Medical Device Industry, 47 FOOD & DRUo L.J. 571, 575 (1992). While
conceding that "[it is unethical to withhold from public attention any document that
impacts on the health of an individual or on the public health generally," Pines
encourages companies to be wary of Congressional requests for documents. Id. He
states that "[tihe FDA seldom takes positive action with product applications while a
company is under investigation." Id. at 577. Still, others argue forcefully for public
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E. The Learned Intermediary's Role120
In Terhune v. A.H. Robins Co.,121 the Washington Supreme
Court stated:
The physician does not confine his practice to the
curing of maladies. He is concerned with the total
health and physical well-being of his patients and
appropriately gives advice upon preventative
measures. Certainly, the insertion of the Dalkon
Shield requires a physician's services, knowledge and
skill. 122
Logic tells us that the insertion of breast implants similarly requires
the learned intermediary's services, knowledge and skill.
The "learned intermediary" doctrine states that manufacturers
may adequately warn prescribing physicians about product risks
without directly warning the ultimate consumers, 12  "presumably
because physicians are in a better position to assess risks for
particular patients."l" The doctrine does not alter the manufacturer's
duty to warn, it simply substitutes the physician for the consumer."
disclosure. Should the Legislature Restrict Secrecy in Settlements?,- YES: Public Policy
Should Favor Protecting Safety and Lives Over Competitive Economic Interests, CONN.
L. TRIB., Feb. 15, 1993, at 19 (stating that the public has "a right to know about
dangerous products or conditions that may affect their safety.").
' In Sterling Drug Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966), the court
characterized the [implant] purchaser's doctor as the learned intermediary between the
purchaser and the manufacturer. In Carmichael v. Reitz, 95 Cal. Rptr. 381 (Cal. App.
2d 1971), the court described the doctor as an intervening party required to exercise his
own independent judgment on the basis of the technical information furnished by the
manufacturer. Id. at 404-05.
121 577 P.2d 975 (Wash. 1978) (holding that IUD manufactures are not liable under
strict scrutiny for risks connected to use of the product, provided the product is properly
prepared and proper warnings are given to prescribing physicians).
12, Id. at 978.
" Desmarais v. Dow Coming Corp., 712 F. Supp. 13, 17 (D. Conn. 1989) ("mhe
manufacture's duty is to warn prescribing physicians."). Most jurisdictions have adopted
the learned intermediary doctrine. Id.
'u Lichtenstein, supra note 114, at 221.
" Desmarais, 712 F. Supp. at 18.
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The doctrine thus provides an exception to the general rule that the
manufacturer of a drug owes a duty to warn the consumer directly
regarding the risks of its prescriptive products. 126  The FDA may,
notwithstanding the foregoing, preclude invocation of the learned
intermediary doctrine where it specifically mandates that warnings be
given to both the physician and patient. 127 In the case of intrauterine
devices, the FDA required physicians, nurses or other trained health
professionals to give prospective patients a manufacturer's brochure,
prior to insertion, which listed perforation (which could lead to
dangerous infection) as a possible adverse effect. 128
In the current breast implant cases, each state must necessarily
juxtapose medical knowledge-i.e. known risks-at a particular time
with product data and vicarious liability.' 29 Clearly, doctors today
are not apt to repeat the information that one breast implant recipient
received in 1969 describing the implant as "a miracle[;] it would last
forever . . . . [Y]ou could run over it with a Mack truck and it
wouldn't break. 1130
' Tayar v. Roux Lab., Inc., 460 F.2d 494, 495 (10th Cir. 1972) (holding
manufacturer not liable for failing to attach warning labels to its product after plaintiff
had an adverse reaction allegedly caused by the product).
1'7 McKee v. Moore, 648 P.2d 21, 25 (Okla. 1982) ("An exception to the general
rule occurs if the FDA has mandated that warnings be given to the patient as well as to
the physician.").
" Id. See 21 C.F.R. § 310.502(b)(2) (1992) (requiring labeling on intrauterine
devices to contain information on possible adverse reactions and requiring that such
information be made available to the patient).
I" Easter et al., supra note 1, at 55. A court in British Columbia has held Dow
negligent in failing to warn the medical community "on a yearly basis, or sooner, if
circumstances warranted it." Dow Held Negligent To Physicians, MED-LWAL ASPECTS
OF BREAST IMPLANTs, July 1993, at 6, 7. The court ordered a new trial to determine
whether the implanting surgeon was negligent. Id. Plastic surgeons in Texas have filed
suit against multiple implant manufacturers and their insurance companies alleging that
they were victims of "shameless, deceitful and malicious conduct" due to the
manufacturer's false representations that the implants were safe. Id. at 8.
0 Primetime, supra note 2. Cf. Rosburg v. Minnesota Mining & Mfg. Co., 226
Cal. Rptr. 299, 304 (Ct. App. 1986) (expert testimony supported finding that breast
implants were not expected to last a lifetime, but concluding only that the ordinary
consumer should expect the possibility of eventual deflation) (emphasis added).
Commenting on the subject, FDA Commissioner David Kessler stated that "[w]e know
more about the life span of automobile tires than we do about the longevity of breast
implants." The MacNeil/Lehrer NewsHour:Update-Breast Implants (Educational
Broadcasting and WGETA television broadcast, July 6, 1993) available in LEXIS, News
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1. Informed Consent
Informed consent means the person providing the professional
treatment or diagnosis "disclose[s] to the patient such alternatives
thereto and the reasonably foreseeable risks and benefits involved as
a reasonable medical practitioner under similar circumstances would
have disclosed, in a manner permitting the patient to make a
knowledgeable evaluation." 131
A window on whether patients believe they gave their
physicians consent on an informed basis follows. Sybil Goldrich,
who had five implant operations before giving up, thinks doctors
should simply read the package inserts, which list the known
complications, to their patients. 1 32 Typical inserts included with the
implants state that it is the surgeon's responsibility to tell the patient
about any possible risk or complication from the implants. 33 Yet less
than one-third of the doctors surveyed by researchers mentioned these
complications to their patients.134 Other women complain that
Library, MACLEH File. Some critics have opined that an implant's average life span
is as little as five to seven years. Rick Weiss, Many Women Choosing Removal of
Silicone Breast Implants, N.Y. TIMES, June 9, 1993, at C13.
131 N.Y. PUB. HEALTH LAW § 2805-d(1) (McKinney 1985) (cited in Skripek v.
Bergamo, 491 A.2d 1336, 1346 (N.J. Super. 1985), cert. denied, 508 A.2d 189 (1985)
(describing this statute as "typical" of at least 10 state legislatures and as a codification
of Canterbury v. Spence, 464 F.2d 772 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972),
and its progeny). Failure to meet the informed consent standard means a physician may
be sued for battery. See Lichtenstein, supra note 114, at 215. The adequacy of the
warning has been cited as the most important issue, and one which is a question of fact
for the jury to decide. Ernest H. Hornsby, Adequate Warnings and Learned
Intermediary in Implant Cases, MED-LEGAL ASPECTS OF BREAST IMPLANTS, May
1993, at 2 (citing Tatum v. Schering Corp., 795 F.2d 925 (1lth Cir. 1986)).
132 Chung, supra note 4, at 4. Doctors have been charged with throwing the inserts
away, usually just prior to inserting the implants, when the patient is under anesthesia
and not likely to contemplate the fine print. See Hornsby, supra note 131, at 3.
133 Chung, supra note 4, at 4. Some doctors report an implant complication rate of
about 40%. James M. Gomez, Devices Languish in FDA Limbo, L.A. TiMS, Apr. 30,
1993, at Al.
134 Chung, supra note 4, at 4. Women who suffer from health problems related to
silicone breast implants say getting accurate information about the product is extremely
difficult. Where to Find Silicone Facts, ST. PETERSBURG TIMES, Dee. 27, 1992, at 5F.
FDA Commissioner David Kessler says that plastic surgeons wanted to convince people
that conclusive evidence that implants are harmful did not exist. See Desperate for Help,
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autoimmune diseases were never discussed as being possibly linked
to breast implants.' When Marie Walsh, another breast implant
victim, approached a surgeon who conducts seminars promoting
implants and asked him about the amount of information he gave to
his patients, he said he read only parts of the insert papers to his
patients.t 36 Asked whether the doctor was reading the part about the
autoimmune disease risks, the doctor's retort minimized the inquiry
by implying Walsh was referring to "every time a woman gets a
cold" Walsh replied, "Doctor, I'm talking about rheumatoid arthritis,
scleroderma, and lupus. Are you describing these conditions to [the
patients]?"' 37 Walsh said the doctor had no response for her. 3 '
Goldrich argues that no one is giving women the information, and
believes if every doctor simply read the package insert to the patient,
the woman would then have enough information to make an informed
decision.
2. Women and Their Doctors: The Boundaries of Informed
Consent and Choice
"Women are not entirely wrong when they reject the rules of
life prescribed for the world, for they were established by men only,
without their consent. "140 Consider the plaintiffs attorney who
supra note 32. That unacceptable standard, Kessler states, would mean "wait[ing] till
there are bodies out there." Id.
13' Physicians treating women often never asked, and therefore never learned, that
their patients (suffering from diseases like rheumatoid arthritis) had silicone implants.
See Zukin, supra note 40, at 4.
136 King, supra note 21, at 7. The plastic surgeons who promoted breast implants
without imparting adequate information to the patient arguably violated the well-known
medical precept "first do no harm," by encouraging healthy people-in the case of
augmentation at least-to undergo surgery. Troutwine, supra note 112, at 49. Some
plastic surgeons' "first harm" was classifying small breasts as a medical problem called
"hypomastia." Id. at 48.
137 King, supra. note 21, at 7.
138 Id.
139 Chung, supra note 4, at 4.
240 Vivian W. Pinn, Women's Health Research: Prescribing Change and Addressing
the Issues, 268 JAMA 1921, 1921 (1992) (quoting MICHEL E. DE MONTAINGE, ESSAYS,
BOOK III (1588)) (editorial).
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commented "if these were products that were going to be cosmetically
put into men, or if most of the doctors who applied them were
women, this [breast implant problem] would never have happened to
the extent it did. 141
In November 1991, the FDA first considered a ban on all
silicone breast implants in both cosmetic and reconstructive surgery
cases because ban proponents asserted a causal link between auto-
immune diseases and the implants. 14 2 Opponents to the ban countered
that the government should not be allowed to take away a woman's
right to make a choice based on an informed decision. 143 One plastic
surgeon in California said that a "small, misguided group of
dissatisfied patients" is being "used as pawns by litigation attorneys
who seek big cash awards" 1  and are fueling the FDA action. 145 The
surgeon further buttressed his argument in opposition to the ban by
asking whether the FDA understood "that if manufacturers lose
seventy percent of their market [the cited percentage of cosmetic
operations] that they will pull out of the market and safety studies
will cease. "i46 This purported arbiter of women's rights, lastly,
condemned the medical establishment's "arrogance" in deciding that
women "informed of all the risks" could not make their own
decisions.1 47 Unfortunately, in light of the foregoing discussion, it
seems an informed decision was rarely, if ever, made.
1 48
In April 1992, the FDA announced that silicone-filled breast
implants would only be available through controlled clinical studies,
assuring their access to mastectomy patients but denying access to
141 Bill Rankin, Atlanta Lawyers at Center of Lawsuits Over Implants, ATLANTA J.
& CONST., Mar. 22, 1993, at Al.
42 In America: Implant Ban? (Kelly News and Entertainment television broadcast,
Nov. 10, 1991) (transcript on file with the New York Law School Journal of Human
Rights).
143 Id.
1U W. Grant Stevens, M.D., Breast Inplants: Don't Take Away Right to Choose,
WALL ST. J., Nov. 14, 1991, at A14.
145 id.
I46 Id.
147 Stevens, supra note 144 (emphasis added).
148 See infra notes 155-69 and accompanying text.
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those who sought implants for cosmetic purposes.149 Although this
appears to deny a choice to both groups of women reaping a shared
cosmetic/psychological benefit from the implants, the difference is
that for women who undergo mastectomies, the option of
reconstructive surgery is viewed as an integral part of the cancer
treatment. 5 °  The FDA's preference for reconstructive surgery
patients over other elective surgery patients in clinical study
participation is also partially explained by societal views as reflected
in insurance companies' willingness to provide benefits to their
insured: Insurance companies usually cover reconstructive surgery
as part of the treatment of breast cancer.' The preference is based
on a belief that the risk-benefit ratio does not favor the unrestricted
use of silicone breast implants in healthy women. 52
In an editorial, the New England Journal of Medicine voiced
one argument against the FDA's selective access-that denying
women the choice to get implants is sexist in light of other risk-
related choices both men and women make (drinking or smoking to
excess, for instance).' 53 The editorial also stated that the FDA ban
has created an unnecessary fear among women who already have
implants and, moreover, ultimately works to effect inappropriate
coercion to participate in clinical studies or do without implants."s4
... Kessler, supra note 111, at 1713. The April 1992 ban on silicone implants will
be in place pending the completion of safety studies, which is not expected until late
1994. Shari Roan, Tune Not On Their Side, Say Women With Implants, L.A. TIMES,
May 18, 1993, at El.
150 Kessler, supra note 111.
51 ld. In France, insurance companies routinely and fully cover breast
reconstruction because reconstruction is considered an inherent part of the treatment for
breast cancer. Suzanne White, In France, Vive La Difference, NEWSDAY, Jan. 31, 1992,
at 52.
152 Kessler, supra note 111.
153 Marcia Angell, Breast Implants-Protection Or Paternalism?, 326 NEW ENO. J.
MED. 1695 (1992) (editorial); Doctors Fight Back, WALL ST. J., June 24, 1992, at A20
(editorial).
"' Angell, supra note 153. Participation in clinical sudies is in fact required by
federal regulations to be voluntary. Id.
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III. THE FDA
Caveat emptor has never been-and will never
be-the philosophy at the FDA. . . . To argue that
people ought to be able to choose their own risks, that
government should not intervene, even in the face of
inadequate information, is to impose an unrealistic
burden on people when they are most vulnerable to
manufacturers' assertions: when they are desperately
ill, when they are hoping against hope for a cure, or
when they are seeking to enhance their physical
appearance. '
In spite of Dr. Kessler's comments, an unrealistic burden was
in fact imposed on people at a time when they were most vulnerable
to manufacturers' assertions."5 6 In 1962, when implants were
introduced, the FDA had no power to regulate the devices.5 7
Congress bestowed the power via the 1976 Medical Device
Amendments Act, 5 8 which requires that medical devices receive pre-
market approval ("PMA") from the FDA based on assessments of
their safety and effectiveness. Unfortunately, since they were on the
market prior to 1976, breast implants were exempted from the Act.' 59
J Kessler, supra note 111.
156 As late as January 1992, 30 years after their introduction, Kessler acknowledged
that the FDA did not have "enough medical evidence to assure women" that breast
implants were safe. Josephine Marcotty, Implant Lawsuits. Flood of Litigation Possible
Because of Health Problems with Silicone Gel, STAR TRIB., Jan. 30, 1992, at 1D.
"7 Sandra G. Boodman, Breast Implants and Birth Defects, WASH. POST, June 23,
1992, at Z14. Similarly, when A.H. Robins began marketing its IUD in the early
1970s, there were no government requirements for pre-market testing, but
recommendations existed that all products be found effective and safe. Tetuan v. A.H.
Robins, 738 P.2d 1210, 1217 (Kan. 1987). In 1969, the World Health Organization
recommended a two year testing program prior to marketing. Id. Medical devices
generally take six months to three years for final approval. See Gomez, supra note 133.
21 U.S.C. § 301-394 (1992).
"5 Easter et al., supra note 1, at 13. Grandfathering the implants was based on the
premise that "generally speaking, more is known about the safety of a device that has
been in use for some time than about one that is newly developed." DEP'T OF HEALTH
& HUMAN SERvIcES, FOOD & DRUG ADMIN., BACKGROUND INFORMATION ON THE
POSSIBLE HEALTH RISKS OF SILICONE BREAST IMPLANTS 1, 1 (Feb. 8, 1991). The PMA
1993] BREAST IMPLANTS 193
These circumstances thus perpetuated the consumer burden described
by Kessler. In 1978, manufacturers and surgeons successfully
lobbied against an FDA proposal which would put implants in a
category requiring vigorous testing."6° Finally, in 1988, twenty-four
years into their market availability, the FDA reclassified implants as
medical devices requiring strict scrutiny, but it also gave
manufacturers two and one half years to provide safety data.1 61
Experts believe that much of the reason for the delay in addressing
the implant problem was political: As part of a general push for
deregulation by the Reagan and Bush administrations, the government
cut back on enforcement in the health sector. 162 This deregulation
allowed companies like Dow Corning to defraud the public and say
different things publicly than they did privately, behind closed
corporate doors.163
system has shielded at least one medical device manufacturer from liability: A federal
appeals court awarded summary judgment to a collagen manufacturer in a failure-to-warn
case, reasoning that the FDA, not judges and juries, was the final authority on the safety
and efficacy of medical devices such as the wrinkle-softening treatment alleged to have
caused injury. King v. Collagen Corp., 983 F.2d 1130, 1140 (1st Cir.), cert. denied,
114 S. Ct. 84 (1993); Linda Himelstein, An Invincible Shieldfor Medical Manufacturers,
Bus. WK., Aug. 9, 1993, at 73. Himelstein predicts that this decision, if upheld, would
effectively ban lawsuits over products which had received the FDA's pre-market "stamp
of approval." Id..
S0 Easter et al., supra note 1, at 13.
16 Id. at 14. 21 C.F.R. § 878.3540 (1991) now requires a PMA filing for silicone
breast implants before their market distribution. It also applies to any silicone gel or
saline-filled prosthesis in commercial distribution prior to May 1976. 21 C.F.R. §
878.3540 (1991). Failure to file results in a prohibition against implant distribution. Id.
PMAs are intended to allow the FDA to gather enough data to make a determination as
to a device's safety, effectiveness, and attendant risks. Lichtenstein, supra note 114, at
211.
162 Primetime, supra note 2, at 13. The medical device industry has been called "one
of Americas most innovative and successful technology-driven industries." See Gomez,
supra note 133. U.S. companies produce nearly half the world's medical devices,
shipping more than one-third overseas and creating a $3.2 billion global trade surplus.
Id.
'" Primetime, supra note 2, at 9. In 1975 (quoting Attorney Dan Bolton who
successfully litigated two California implant suits: "This is an example of outright fraud
by Dow-Corning. Internally they are saying one thing ... [Plublicly they're saying the
complete opposite."). When a competitor had developed a new implant preferred by
surgeons, Thomas Talcott, a member of a Dow task force ordered to produce a new
implant, said memos circulated weekly counting down how much time was left before
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By 1991, four manufacturers' PMAs (including Dow's) had
received FDA approval which allowed the product to remain on the
market while the FDA conducted a more thorough review.' The
Task Leader of the Breast Prosthesis PMA Task Force, Diana
Zuckerman, had scathing criticisms of the FDA decision to grant the
PMA.165 FDA statisticians explicitly recommended that the PMAs
not be filed due to major flaws in the studies. Dow's clinical studies
were "'so weak that they cannot provide a reasonable assurance of
the safety and effectiveness of these devices[,]' because they provide
'no assurance that the full range of complications are included, no
dependable measure of the incidence of complications, no reliable
measure of the revision rate and no quantitative measure of patient
benefit.'"" Dr. Zuckerman believed, based on her discussions with
FDA officials, that the FDA accepted the PMAs primarily out of
concern that a lengthy appeals process initiated by the manufacturers
would delay the release of information to the public because safety
studies would be suspended during that time. 67 Dr. Zuckerman
believed, consequently, that in the interim, approximately 100,000
more women would get implants, "not knowing that they are serving
as guinea pigs in a vast, uncontrolled clinical trial." 68
Additionally, in September 1991, the FDA published patient
risk information sheets for manufacturers to send to physicians for
subsequent dissemination to their respective patients. 69 As of May
trade show and doctor meeting deadlines. According to Talcott, these deadlines were
met at the expense of product safety. Id. at 11. This type of activity illustrates the "all-
too-familiar tale of the manufacturers' paramount desire to rush a product to market, to
use human beings as guinea pigs without their knowledge and [to] callously disregard all
indications that their products pose a serious health risk until forced to . . .by the civil
justice system and the regulatory agencies." See Zukin, supra note 35, at 8.
"6 Memorandum from Diana Zuckerman, Professional Staff Member, House of
Representatives Human Resources and Intergovernmental Relations Subcommittee of the
Committee of Government Operations to Rep. Ted Weiss, (D-N.Y.) Chairman (Sept.
12, 1991), reprinted in BREAST IMPLANT LrTIO. 73 (1992).
16 Id.
.. Id. at 73-74.
67 Id. at 77.
168 Id.
169 See Easter et al., supra note 1, at 16. The risk sheets explained that the implants
could break due to injury or normal wear over time, releasing the silicone gel filling,
and that it was unknown whether this was harmful to health in the long run. It also
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1992, the FDA's medical device tracking requirements prohibit the
distribution of breast implants to any physician who has not collected,
maintained or reported tracked information.17 Manufacturers
themselves are prohibited, however, from reporting unsubstantiated
comments and concerns from physicians under FDA regulations.171
The FDA regulations have been deemed minimal standards, but drug
companies are not prohibited from providing additional warnings and
information.' 72 Meanwhile, doctors opine that patient management
decisions should be left to the practicing profession, not the FDA. 73
FDA Commissioner David Kessler and the Co-Chairs of the
Advisory Committee on the FDA, Dr. Charles Edwards and Dr.
Lawrence Horowitz, all say that the FDA is in crisis and feel that it
cannot carry out all that is mandated of it by law. 74 Yet, even as the
FDA has expressed concern about getting information to the public,1 75
stated that "[tihere is no scientific evidence at present that women with breast implants
have an increased risk of these [autoimmunel diseases, but the possibility cannot be ruled
out." Id. at 63 (emphasis added). Saline-filled implants were distinguished as not
incurring the same potentialities of the silicone gel filled prostheses, but "since both
types of implants have a silicone rubber envelope, an increased risk of autoimmune
diseases or cancer is possible even for the saline-filled implants." Id. A Congressional
report stated that the informed consent form was changed to minimize the implants' risks
at the behest of doctor's organizations, a charge the FDA denies. Early Prime: FDA
Angry Over Allegations They're Lax on Implants (CNN television broadcast, Jan. 6,
1993) available in LEXIS, News Library, CNN File. The report concludes that a
number of women are still receiving implants purely for cosmetic reasons, despite the
FDA ban enacted in January 1992. Id. See also infra notes 191, 193 and accompanying
text (discussing saline implants and their dangers).
,70 See 21 U.S.C. § 360i(e) (1990); 57 Fed. Reg. 10,707 (1990); Easteret al., supra
note 1, at 16-17.
17l Savina v. Sterling Drug, 795 P.2d 915, 929 (Kan. 1990) (discussing how FDA
regulations prohibit drug manufacturers from reporting insubstantial comments and
concerns from doctors). In disclosing adverse reactions, manufacturers are to list only
known, not theoretical, hazards. 21 C.F.R. § 201.57(d) (1989).
'7' Savina, 795 P.2d at 931.
'7 Palmer v. A.H. Robins Co., Inc., 684 P.2d 187, 205 (Colo. 1984).
,"' Newsmaker Sunday: Has the Public Lost Confidence in the FDA? (CNN
broadcast, May 19, 1991) available in LEXIS, News Library, CNN File.
170 See Zuckerman, supra note 164, at 77.
196 NYLS JOURNAL OF HUMAN RIGHTS [Vol. XI
its own laws violate the Freedom of Information Act ("FOIA"). 76
In Teich v. FDA, the court charged the FDA with "attempting to
evade the FOIA for its own purposes and for those of its
regulatees. ,"' The FDA had sought to invoke an exemption created
for trade secrets and commercial or financial information. The court
strongly stated that "if silicone breast implants are, in fact, a 'killer
product,' it is urgent that this information be made public
immediately. This is precisely one of the reasons for which the
FOIA was created."178
With manufacturers largely interested in their bottom line,
doctors who believe that drug manufacturers have a duty to warn
them of worst case scenarios,179 and an FDA which ineptly relies on
voluntary submissions instead of pursuing avenues "certainly open to
it," 8 it seems no wonder that it took judicial action to motivate
physicians, corporate officials, lawyers and insurers alike to become
more familiar with the use of silicone in the human body and its
potential complications.' The human guinea pigs had suffered long
enough.
"76 See Teich, 751 F. Supp. at 245. 21 C.F.R. § 20.44 provides that information
submitted to the FDA may be kept separate and confidential, pending determination
whether the information would be exempt from a mandatory FOIA request. If the FDA
determines that some or all of the information is not protected under an FOIA
exemption, the submitting company may withdraw the information, with no copies being
withheld from the FDA. Id. at 246. Presubmission was deemed "nothing more than an
attempt to get around the FOIA." Id. at 248.
t7 751 F. Supp. 243, 249 (D.D.C. 1990). Between 1987 and 1988, the FDA was
unable to locate the requested studies due to agency reorganization. Id. at 246.
178 Id. at 249.
1' See, e.g., Savina v. Sterling Drug, 795 P.2d 915, 930 (Kan. 1990) (plaintiff's
expert witness, a doctor who treated patients allegedly suffering damages caused by
defendant's product, testified that he believed that "the drug manufacturer had a duty to
fully advise the physician of the worst case scenario to enable him to react appropriately
when symptoms ... [associated with the drug's administration] occurred.").
110 Teich, 751 F. Supp. at 251.
181 Easter et al., supra note 1, at 54-55.
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IV. Looking Ahead
In June 1992, a Florida writer stated that media interest in
silicone breast implants was fading,182 but indicia suggest otherwise:
The controversy surrounding breast implants has been called "a
harbinger of a fundamental change in the regulatory attention devoted
to the medical devices industry.""' The industry is said to be at the
top of the FDA's, the media's and Congress' agenda, and "is likely
to remain there for some time.""' The Safe Medical Devices Act of
1990185 broadened the FDA's authority to increase vigilance over the
safety of marketed products,186 and the FDA is demanding that
medical device data meet higher standards than before.1 7
"n Bruce Vielmetti, Implants Making New Case History for Local Lawyers, ST.
PETERSBURG TIMES, June 1, 1992, at 9.
183 Pines, supra note 119, at 571.
18 Id.
'8 Pub. L. No. 101-629, 104 Stat. 4511 (1990).
18 Pines, supra note 119, at 571. FDA critics count among other agency
shortcomings evident in the breast implant debacle the fact that since April 1992, it has
not monitored the use of silicone breast implants, despite promises to the contrary.
Troutwine, supra note 112, at 50. The FDA recently announced that manufacturers will
be required to keep track of silicone breast implant recipients to enable rapid
communication in the event malfunctions arise. Inplant Manufacturers Must Track
Recipients, WASH. POST, Sept. 7, 1993, at Z5.
'8 Pines, supra note 119, at 572. The FDA conducted little safety review of
medical devices in the past; some tests and applications for approval were "not up to the
level offifih-grade science." Philip J. Hilts, FDA to Toughen Testing of Devices, N.Y.
TIMES, Mar. 5, 1993, at A18 (quoting Dr. Bruce Burlington, the FDA's chief of the
Center for Medical Devices) (emphasis added). Thus, a House panel's opinion that there
is an "intolerable" situation at the Center for Devices & Radiological Health-the FDA
agency that regulates medical devices-is not surprising. House Panel Attacks Device
Regulators, HEALTH LEois. & REG., June 9, 1993 (Vol. 19, No.23). FDA
Commissioner Kessler recently announced the creation of Medwatch, a program
designed to encourage health care professionals to report suspicions that a device is
causing an adverse reaction. Sybil N. Goldrich & Kathleen W. Anneken, R.N.,
Medwatch: FDA's New Reporting Program, COMMAND TRUST NETWORK BREAST
IMLANT INFO. NETWORK (Command Trust Network, Inc., Covington, Ky.) Summer
1993, at 1; Philip J. Hilts, U.S. Encourages Reporting Of Adverse Medical Reactions,
N.Y. TIMES, June 2, 1993, at A17; Kessler estimated that 1-10% of serious adverse
reactions from drugs or medical devices are currently reported to the FDA. Marlene
Cimons, Doctors Urged to Warn of Bad Drug Reactions, L.A. TIMES, June 2, 1993, at
All.
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The coming years will produce increased, not decreased,
media attention. Well over 1,000 federal cases alone have been
transferred to the Multi District Litigation in Alabama, 88 insuring that
lawyers, too, will continue to be involved in the matter for a decade
or more. The Los Angeles District Attorney's office has instituted
a criminal investigation to determine whether Dow and its managers
withheld information about the implants, 89 and there has been a
Congressional request for the Justice Department to investigate
whether Dow "misled women, plastic surgeons and [the] government
on [the] safety of silicone breast implants."'90
Expanding its quest beyond silicone, the FDA has now
initiated the same sort of monitoring process for saline implants as
that in place for the silicone variety.1 9' Women who chose to have
their silicone implants replaced with saline implants-thinking they
were safer than what was already inside them-may be in trouble.
Hard silicone shells encapsule the saline inside, and can cause the
same problems as the silicon-filled implants. 92 Further, in rare
cases, the saline can become contaminated and grow bacteria. 93 This
11 Susan C. Zuckerman, State Breast Implant Cases Aided by MDL Legwork, MED.
LEGAL ASPEcTS OF BREAST IMPLANTS, Dec. 1992, at 1, 3. See note 72 and
accompanying text. Another report numbered the combined federal cases in Alabama
at 2,000 and cited 1,000 state cases in California alone. Burton, supra note 22, at B1.
'" Ronald Begley, Dow Corning Ponders an Exit, CHEMICAL WK., Mar. 4, 1992,
at 8.
'90 Bruce Ingersoll, Criminal Inquiry of Dow Corning To Be Sought, WALL ST. J.,
Feb. 13, 1992, at A3. A federal grand jury in Baltimore, Maryland is investigating
whether Dow misled patients and physicians by telling them silicone implants were safe
despite having data suggesting otherwise. Implant Allegations Go To A Grand Jury,
Bus. WK., Mar. 1, 1993, at 46.
1' FDA to Toughen Standardsfor Saline Breast Implants, Cmu. TRIB., Jan. 6, 1993,
at 7; The FDA can state neither that the saline implants are safe nor unsafe. Prime
News: Medical Jury is Still Out on Saline Inplants (CNN television broadcast, Jan. 5,
1993) available in LEXIS, News Library, CNN File.
19 Rigdon, supra note 59.
I9 d. Dr. Pierre Blais, a Canadian physician who used to regulate breast implants
for his government, says that the saline implants are contaminated and that
microorganisms that can grow inside could be lethal. Expert's Corner, MED.-LEGAL
ASPECTS OF BREAST IMPLATS, Dec. 1992, at 5. Blais says the saline implant design
is faulty, allowing the organisms to escape and infect the patient; moreover, the devices
leave the factory unclean, and he has found "mold, fungus and viruses imbedded in the
plastic." Id.
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ongoing, dangerous situation reflects the grave need for the FDA to
continue stepping up its vigilance regarding all types of breast
implants.
With the dangerousness of silicone and saline implants gaining
recognition,1" other alternatives to meet aesthetic demands are
emerging. One manufacturer developed an implant with a filling
called "Misti Gold," which is eliminated by urination in case of a
rupture, but sales of this product ceased in the U.S. and overseas by
the end of April 1992."95 Fat injections have received renewed
enthusiasm as a possible alternative to unsafe implants, 1 but they too
pose problems because they may calcify and thereby obstruct accurate
mammogram readings.197 The injected fat may evince cancer growth
where none exists, thus producing so-called "false positive"
mammography results.19 Another surgical option is the "free-flap
microsurgery process," '9 in which a flap of the patient's back,
abdomen or buttocks is taken and reshaped for attachment to the
desired area.2' Non-surgical options to implants include a silicone
prosthesis which fits inside bras or attaches to breasts.0 1
194 Dow Coming Corporation has reported that silicone gel has been found to be a
strong irritant of the immune system in animals. Philip J. Hilts, Breast Implants Found
to Irritate Immune System, N.Y. TIMES, Mar. 20, 1993, at 8. See FDA Tells Breast
Implant Firms to Notify Women of New Research, REUTERS BUS. REP., Mar. 20, 1993,
available in LEXIS, News Library, REUBUS File.
'" Bioplasty, Inc. Announces Second Quarter 1993 Results of Operations, PR
NEWSWIRE, March 18, 1993, available in LEXIS, News Library, PRNEW5 File.
"' Women originally tried to use body fat to enlarge their breasts in 1916, but the
procedure failed because the fat was eventually absorbed into the body. Lichtenstein,
supra note 114, at 207.
"9 Surgeon Says Fat Injections for Breast Enlargement Pose Threat, UPI, Feb. 17,
1993, available in LEXIS, News Library, UPI File. See Donahue, supra note 4, at 12-
13.
" Surgeon Says Fat Injections for Breast Enlargement Pose Threat, supra note 197.
However, the doctor who was cited for the foregoing proposition also stated that "saline-
filled implants can accomplish similar [to silicone-filled] results without the risk of the
potentially dangerous side effects." Id. This appears, at best, to be an uncertainty. See
Rigdon, supra note 59.
199 A Safer Alternative to Silicone Implants?, MED.-LEOAL ASPECTs OF BREAST
IMPLANTS, Dec. 1992, at 8.
2W Id.
201 Id.
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Many women were lulled into believing that implants were
risk-free. 2° Organizations like The Medic Alert Foundation2 °3 and
the Command Trust Network2' now help remind women that the
implants were not risk free at all. These organizations keep women
and their physicians current on the developing body of information
regarding implants through a worldwide registry, updates and
notification services.2 °0 According to their founders, the networks
were necessary owing to the plastic surgeons' resistance to the idea
that implants could be connected to any health problems. 206 Long
term effect studies for autoimmune disease and cancer are underway
at the University of Michigan and New York University, and are
planned at the National Cancer Institute. 207 One class action in
Virginia seeks a program to monitor the safety of implants.20 8
Concurrent to the emerging breast implant support networks,
women's health care is receiving increased attention as health care
providers debate whether to create a new specialty focusing on
women's health concerns exclusively. 2°
2I2 Salle R. Crooks et al., Quick Relief for Migraine Sufferers, USA TODAY, Aug.
1, 1991, at 6D. A Congressional report accusing the government of failing to act and
the implant industry of trying to conceal the problems said that women were misled for
years about the safety of some breast implants. Report: Implants'Risks Covered Up, ST.
PETORsBuRO TIMES, Jan. 7, 1993, at 8A. One member of Congress said the report was
premature and contains several errors, and that the news media "should discern between
the work of Congress and committees." Rep. Craig Thomas (R-Wyo.), Breast Implant
Report Was Premature, N.Y. TIMES, Jan. 23, 1993, at 20 (letter to the editor).
'0 See Missouri, Legal Aid Baring Teeth Over Medicaid Cuts, CHI. TRIB., Feb. 14,
1992, at C7.
I Marian Segal, Silicone Implants: Available Under Tight Controls, 26 FDA
CONSUMER 6, 7 (1992).
20 See supra notes 203-204.
Desperate for Help, supra note 32.
Id. The University of Michigan study is sponsored by Dow Coming. Burton,
supra note 22.
' Saundra Torry, The Race to Represent Breast Implant Victims, WASH. POST,
Mar. 9, 1992, at F5.
I Tamar Lewin, Doctors Consider a Specialty Focusing on Women's Health, N.Y.
TIMEs, Nov. 7, 1992 at 1; Commentary, American Women's Health Care: A Patchwork
Quilt With Gaps, 268 JAMA 1918, 1919 (1992); Pinn, supra note 140, at 1921
(discussing the unique health concerns of woman and the need for increased study in this
area).
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V. Societal Perspective
Women have come a long way since the 17th century, when
philosophers imposed the bias of male superiority in analyzing natural
order and reproduction. 2 0 But as recently as the early 1900s, debates
over whether or not to lift the legal restrictions enacted against
women in Britain and the United States centered on whether women
could be considered "persons," with rights to higher education, public
office, and voting.2 1' Today, some feminists argue that society's
preoccupation with women's physical appearance results from the
desire of men to assert their supremacy over the opposite sex."' The
individual and financial success of increasing numbers of women
working outside the home, the logic goes, leads men to rebel by
making women feel physically inferior, destroying their confidence
and, presumably, assuring women's insecurity and dependence. 1 3
Added to (or part of) this volatile mixture are plastic surgeons who
have joined forces with manufacturers in a massive lobbying effort to
convince both the public and the government that the health concerns
surrounding silicone implants are a creation of hysterical women and
the plaintiff's trial bar.21 4 It appears that not much has changed.
The debate over whether or not women should have chosen
to get implants relates as much to the matter of choice (including
when the choice should be suspended) as it does to the manner in
which women have been and continue to be socialized in our
culture.21 5 Countless participants in the breast implant debate, like
the DES and Dalkon Shield victims, have assailed the medical,
manufacturing and regulatory communities for using women as
210 CYNTHIA F. EPSTEIN, DECEPTIVEDISTINCTIONS: SEX, GENDER, AND THE SOCIAL
ORDER 28 (1988).
21 Id. at 125.
22 Troutwine, supra note 112, at 48.
213 Id.
214 See Zukin, supra note 40, at 5. District Court Judge Pointer, who presided over
the Alabama Multidistrict Litigation, has ruled that psychiatric records do not have to
be routinely turned over and denied a defendant's motion to compel same. Sybil
Shainwald, Defense Not Entitled to Psychiatric Records, MED.-LEGAL ASPECTS OF
BREAST IMILANTS, July 1993, at 7. Shainwald interpreted Pointer's decision as a
declaration that "pain and suffering" is not a psychiatric injury. Id.
215 See supra notes 4, 11, 12, 58 and accompanying text.
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society's guinea pigs."' The fact is that no society depends solely on
the process of socialization, however gross, to motivate its members
to conform to acceptable goals and expectations: All societies, "in
spite of the cultural belief that allocations of social roles by sex are
predetermined by God or by nature. . . take great care to establish
laws, or rules where no formal body of law exists, to ensure that
individual's real roles come close to the culture's ideal roles. ,2 17 Is
the pretty, undisfigured-and, therefore, presumably desirable-
woman the appropriate governing role for women?
Beyond perpetuating idealized images of women and reaping
profits from their insecurities, the implant controversy has entered on
the same playing field as the abortion controversy-should women
have the freedom to preempt the government's handling of their
bodies?218 The difference with implants is twofold: Women should
not be able to choose a device that has never been adequately
tested,21 9 and the goal of meeting cultural ideals of feminine beauty220
has no viable parallel in the abortion right. Most importantly, the
freedom involved here is the freedom to be ignorant.221 Informed
consent requires both information and choice.222 In the case of
implants, women have had neither.
VI. Conclusion
Until manufacturers, doctors and regulatory bodies realize that
women can no longer be unwitting human experiments, the judiciary
and dedicated litigants are needed to punish those who disregard
women's rights and to eradicate laws which discriminate against
216 See supra notes 4, 12, 58 and accompanying text. See also supra note 12 and
accompanying text (discussing how doctors at Dow Coming injected humans with
silicone without disclosing that they were part of an experiment).
217 See Epstein, supra note 210, at 118-19.
218 Judy Foreman, Implants: Is Uninformed Consent a Woman's Right?, BOSTON
GLOBE, Jan. 13, 1992, at 25.
219 Id.
2 Id.
22' Id.
Ia See supra notes 131-50 and accompanying text.
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them. 3 The answer lies in a more vigilant FDA, supported by the
body politic, to carry out its mission as the buffer between
manufacturers and the consuming public: A thirty year lag time
between market availability and governmental action is unacceptable.
The FDA should conduct its own product testing instead of relying
on the testing of manufacturers whose activity it seeks to regulate.2'
Further, to avoid the inherent dangers in product liability suits which
are "settled and sealed, ''225 the FDA should acquire subpoena power
to get company documents in order to catch problems before they rob
women and other members of the public from the opportunity to
make fully informed decisions.226
Society's thirst for female beauty is not likely to whittle
awayany time soon, nor is it likely that manufacturers will stop trying
to meet these desires. It is imperative, therefore, that the government
,* For further data on sex discrimination laws, see Epstein, supra note 217 at 121-
23.
Lichtenstein, supra note 114, at 227. A recent FDA report has suggested joint
FDA-industry clinical trials to speed up the approval process, which Representative John
Dingell (D-Mich.) stated remains in an "'unconscionable'" paralysis." See Gomez,
supra note 133. The approval process can greatly deplete a company's financial
resources and constrict its ability to conduct other research and development. Id.
225 See supra note 109 and accompanying text.
' See Lichtenstein, supra note 114, at 228-29.
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take responsibility for insisting on full disclosure of all risks
associated with breast implants.227 Just as ignorance is no excuse in
the law,228 it cannot be a part of any true choice.
Zoe Panarites
David Kessler stated: "Everybody's responsible [for this 'great tragedy']. The
manufacturers who sold these products, the doctors who implanted it and this agency [the
FDA] who, over a period of time, didn't call the plastic surgeons and the manufacturers
on the carpet." Desperate for Help, supra note 32. Results of a survey which asked
who's to blame assigned the following culpability shares: manufacturers, 35%, vanity,
24%, government, 21%, and doctors, 14%. Fever Line, U.S. NEws & WORLD REP.,
Sept. 20, 1993, at 18. Dow's proposed settlement, see supra note 63, has been
interpreted as its acceptance of "legal, moral and financial responsibility for their
defective products" by Beverly Hills attorney Jeffrey W. Steinberger. Statement and
Media Legal Contact Regarding Defective Silicone Breast Implant Settlement, Bus.
WIRE, Sept. 10, 1993, available in LEXIS, News Library, WIRE File.
' United States v. Int'l. Minerals & Chem. Corp., 402 U.S. 558, 562 (1971).
Regarding the FDA's ignorance, Commissioner Costlier stated, "30 years of [breast
implant] use and I don't have the answers to basic questions." Desperate for Help,
supra note 32.
